AbbVie/$ABBV

1D1W1MYTD1Y5YMAX

About AbbVie

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Ticker
$ABBV
Sector
Health
Primary listing
NYSE
Employees
57,000
Headquarters
North Chicago, United States
Website
www.abbvie.com

AbbVie Metrics

BasicAdvanced
$467B
74.68
$3.54
0.28
$6.83
2.62%

What the Analysts think about AbbVie

Analyst ratings (Buy, Hold, Sell) for AbbVie stock.
Analyst projections of the future price of AbbVie stock.

Bulls say / Bears say

AbbVie’s post-Humira replacement is working. In the second quarter, Skyrizi and Rinvoq sales rose about 24% each, lifting immunology revenue 15.1%, while the company raised 2026 revenue guidance by $300 million to roughly $67.6 billion. (Reuters, AbbVie)
The completed $10.9 billion Apogee acquisition strengthens AbbVie’s longer-term immunology pipeline. Its late-stage zumilokibart programme targets atopic dermatitis, while related assets could expand the company into asthma and COPD. (Reuters, AbbVie)
Neuroscience is emerging as a meaningful second growth pillar. Second-quarter neuroscience revenue rose 20.3%, helped by Vraylar, Botox Therapeutic, migraine medicines and the early contribution from Vyalev. (AbbVie, AbbVie)
Humira’s erosion remains severe and has not stopped. Second-quarter sales fell 35.9% to $756 million as biosimilars took share, leaving AbbVie increasingly reliant on the continued momentum of Skyrizi and Rinvoq. (Reuters, AbbVie)
The Apogee deal adds execution and valuation risk before it produces meaningful revenue. AbbVie paid about $10.9 billion and cut its 2026 adjusted EPS guidance by four cents at the midpoint, including 14 cents of expected acquisition dilution; the acquired clinical assets could still fail in later trials. (Reuters, AbbVie)
Pricing policy, competition and product setbacks are weighing on other franchises. Imbruvica sales fell 29.4% because of Inflation Reduction Act pricing and competitive pressure, while the FDA declined to approve AbbVie’s experimental wrinkle treatment over manufacturing concerns. (AbbVie, Reuters)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2026.

AbbVie Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

AbbVie Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

AbbVie News

AllArticlesVideos

US FDA approves AbbVie's drug for Parkinson's disease

Reuters3 days ago

AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline

MarketBeat2 weeks ago

AbbVie's migraine treatment meets late-stage study goal

Reuters3 weeks ago

Funds containing AbbVie

AllEURGBPUSD
Funds
Fund name
Fund size
$ABBV weighting
iShares S&P 500 Health Care Sector€IUHE
€125M7.59%
iShares MSCI World Health Care Sector Advanced€CBUF
€606M5.73%
iShares MSCI USA Quality Dividend ESG£HDIQ
£578M3.13%
WisdomTree Global Quality Dividend Growth£GGRG
£1.9B2.77%
Amundi S&P 500£500G
£6.6B2.23%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.